MSI-H/dMMR Advanced Colorectal Cancer: Pembrolizumab vs Chemotherapy
Posted: 05/04/2022 | By: Melissa E. Fryman, MS

Question 1 of 5

Consistent with the data published in the interim analysis for KEYNOTE-177, data from the final analysis show that progression-free survival improved with first-line pembrolizumab treatment vs chemotherapy. Median progression-free survival rates observed at the updated analysis were:

Choose 1